News Releases

- SRA737 Phase 1/2 Monotherapy and SRA737+LDG (Low Dose Gemcitabine) trials selected for poster presentations on June 1st - - Sierra to hold Analyst & Investor Event at 6:00 am CT on June 3rd...

Momelotinib regulatory pathway clarity anticipated in Q2 2019 - - SRA737 Phase 1/2 preliminary clinical data anticipated at the 2019 ASCO Annual Meeting - VANCOUVER, May 8, 2019 /CNW/ - Sierra...

Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology and...

- Compelling preclinical data for its Cdc7 inhibitor, SRA141, indicate a potentially novel and distinct mechanism of action - VANCOUVER, April 3, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA),...

- Late-breaking oral presentation reports profound, durable synergistic activity for immunotherapy combined with SRA737+LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small cell lung...

- Dr. Christian Hassig, CSO, scheduled to present at 10:00 a.m. ET on March 13, 2019 - VANCOUVER, March 5, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development...

- Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 preliminary data anticipated in H1 2019 - VANCOUVER, Feb. 28, 2019 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a...

- Late-breaking oral presentation to report preclinical mechanistic and efficacy data for immunotherapy combined with SRA737 + LDG, its Chk1 inhibitor plus low dose gemcitabine (LDG), in small...

- "Addressing Intrinsic & Acquired PARP Inhibitor Resistance Through Chk1 Inhibition" scheduled for 9:00 am ET on January 30 in Boston - VANCOUVER, Jan. 23, 2019 /CNW/ - Sierra Oncology, Inc....

- 44% of transfusion dependent myelofibrosis patients (multi-study aggregate N=152) were transfusion free for at least 12 weeks; 49% were transfusion free for at least 8 weeks - - Data from...

- SRA737 synergizes with immune checkpoint blockade in small cell lung cancer (SCLC) – - Activates immune signaling STING pathway - - Data reported at the AACR Conference on Tumor Immunology and...

- Call to include Dr. Srdan Verstovsek and will discuss emerging clinical data demonstrating momelotinib's unique anemia benefit in patients with myelofibrosis - VANCOUVER, Nov. 27, 2018 /CNW/ -...

- SRA737 demonstrates preclinical efficacy in aggressive CCNE1-amplified and MYCN‑overexpressing high-grade serous ovarian cancer patient-derived xenograft (PDX) models - - PDX models were...

- Novel oral Cdc7 inhibitor, SRA141, demonstrates competitive target selectivity and robust efficacy in several cancer models - VANCOUVER, Nov. 13, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq:...

- Momelotinib regulatory pathway clarity anticipated in H1 2019 - - SRA737 Monotherapy and LDG Combination trial preliminary data anticipated in H1 2019 - VANCOUVER, Nov. 8, 2018 /CNW/ - Sierra...

- "Targeted Therapeutics for Hematology & Oncology" scheduled for 5:20 p.m. GMT on November 14, 2018 - VANCOUVER, Nov. 7, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug...

– Biomarker data obtained from 41 transfusion dependent patients support ACVR1 mechanism of action for momelotinib's anemia benefit in myelofibrosis – – 34% of patients achieved RBC...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing targeted therapeutics for the treatment of patients with significant unmet needs in hematology...

- Up to $15 million available in three $5 million tranches; additional $25 million potentially available - VANCOUVER, Aug. 22, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage...

- More than 1,200 patients treated to date with momelotinib, including in two Phase 3 trials; ongoing therapy for more than seven years in some patients - - Demonstrated meaningful anemia-related...

- SRA737 Monotherapy trial prioritized for ovarian cancer; targeting enrollment of 65 patients with preliminary data anticipated in H1 2019 - - SRA737 LDG Combination trial to be amended and...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

- SRA737 Monotherapy Phase 1/2 trial expanded to enroll CCNE1-driven ovarian cancer cohort - - SRA737 Low-Dose Gemcitabine Combination Phase 1/2 trial advanced into cohort expansion phase - -...

- Two posters reporting activity for SRA737 with PARPi (in CCNE1-driven cancers, HRR proficient cancers, and PARPi-resistant cancers) reinforce the potential broad clinical utility of this...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer,...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer,...

- Janssen supply agreement for ZEJULA® (niraparib) facilitates novel PARPi combination trial with SRA737 in prostate cancer - - SRA737 clinical development program significantly expanded - -...

- Ongoing SRA737 clinical studies expanded to target aggregate enrollment of 200 patients across ten cancer indications – - Adding new SRA737 monotherapy cohort for CCNE1-driven ovarian cancer -...

- Janssen to supply PARP inhibitor niraparib for Sierra's Phase 1b/2 combination trial with Chk1 inhibitor SRA737 - VANCOUVER, Feb. 27, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

- Sierra also to present at the BIO CEO & Investor Conference in New York on February 12th - VANCOUVER, Feb. 6, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development...

- "Leveraging Synthetic Lethality to Enhance Clinical Trials with SRA737, a Next-Generation Chk1 Inhibitor" scheduled for 2:15 pm ET on February 1, 2018 in Boston - VANCOUVER, Jan. 29, 2018 /CNW/...

Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...

- Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK - - On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to...

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 - VANCOUVER, Nov. 7, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug...

- SRA737 demonstrates synergy with replication stress-inducing agents - - SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models - - SRA737 potentiated by novel sub-therapeutic...

- Dr. Allen, key contributor in the advancement of PARP inhibitors, to support Sierra in developing next-generation DDR therapeutics - VANCOUVER, Oct. 25, 2017 /CNW/ - Sierra Oncology, Inc....

- Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models...

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 11:00 am PT on October 17, 2017 - VANCOUVER, Oct 11, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug...

- Dr. Leonard Post, Dr. Eric J. Brown, and Dr. Geoffrey I. Shapiro to discuss DDR scientific and clinical development - VANCOUVER, Oct. 4, 2017 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical...

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 8:35 am ET on September 26, 2017 - VANCOUVER, Sept. 20, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug...

Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with cancer, today...

- Leading experts in DDR biology, chemistry and medicine to help maximize the potential clinical and commercial opportunities for Sierra's drug candidates – VANCOUVER, Aug. 15, 2017 /CNW/ -...

- On track to provide preliminary update from Chk1 inhibitor SRA737 clinical trials in early 2018 - - Phase 1 trials amended and enhanced to prospectively enroll patients with genetically-defined...

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 1:55 pm ET on August 15, 2017 - VANCOUVER, Aug. 2, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug...

- Presenting two posters describing innovative trial designs leveraging Chk1 synthetic lethality at the ASCO 2017 Annual Meeting - VANCOUVER, June 5, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ:...

- Selection patent issued for SRA737 covers the compound explicitly and extends initial protection out to 2033 - VANCOUVER, May 30, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical...